Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703–19. https://doi.org/10.1038/s41375-022-01613-1.

Article  PubMed  PubMed Central  Google Scholar 

Cazzola M. Myelodysplastic syndromes. N Engl J Med. 2020;383:1358–74. https://doi.org/10.1056/NEJMra1904794.

Article  CAS  PubMed  Google Scholar 

Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364:2496–506. https://doi.org/10.1056/NEJMoa1013343.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28:241–7. https://doi.org/10.1038/leu.2013.336.

Article  CAS  PubMed  Google Scholar 

Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70. https://doi.org/10.1016/s0092-8674(00)81683-9.

Article  CAS  PubMed  Google Scholar 

Levine AJ. p53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer. 2020;20:471–80. https://doi.org/10.1038/s41568-020-0262-1.

Article  CAS  PubMed  Google Scholar 

Bejar R, Stevenson KE, Caughey B, Lindsley RC, Mar BG, Stojanov P, et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014;32:2691–8. https://doi.org/10.1200/JCO.2013.52.3381.

Article  PubMed  PubMed Central  Google Scholar 

Della Porta MG, Galli A, Bacigalupo A, Zibellini S, Bernardi M, Rizzo E, et al. Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2016;34:3627–37. https://doi.org/10.1200/JCO.2016.67.3616.

Article  PubMed  PubMed Central  Google Scholar 

Versluis J, Saber W, Tsai HK, Gibson CJ, Dillon LW, Mishra A, et al. Allogeneic hematopoietic cell transplantation improves outcome in myelodysplastic syndrome across high-risk genetic subgroups: genetic analysis of the blood and marrow transplant clinical trials network 1102 study. J Clin Oncol. 2023;41:4497–510. https://doi.org/10.1200/JCO.23.00866.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017;129:1753–62. https://doi.org/10.1182/blood-2016-06-724500.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun YQ, Xu LP, Liu KY, Zhang XH, Yan CH, Jin J, et al. Pre-transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors. Cancer Commun. 2021;41:333–44. https://doi.org/10.1002/cac2.12140.

Article  Google Scholar 

Schroeder T, Wegener N, Lauseker M, Rautenberg C, Nachtkamp K, Schuler E, et al. Comparison between upfront transplantation and different pretransplant cytoreductive treatment approaches in patients with high-risk myelodysplastic syndrome and secondary acute myelogenous leukemia. Biol Blood Marrow Transpl. 2019;25:1550–9. https://doi.org/10.1016/j.bbmt.2019.03.011.

Article  Google Scholar 

Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 2022. https://doi.org/10.1056/EVIDoa2200008.

Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65. https://doi.org/10.1182/blood-2012-03-420489.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malcovati L, Della Porta MG, Strupp C, Ambaglio I, Kuendgen A, Nachtkamp K, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica. 2011;96:1433–40. https://doi.org/10.3324/haematol.2011.044602.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weinberg OK, Siddon A, Madanat YF, Gagan J, Arber DA, Dal Cin P, et al. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. Blood Adv. 2022;6:2847–53. https://doi.org/10.1182/bloodadvances.2021006239.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Luo Y, Xiao H, Lai X, Shi J, Tan Y, He J, et al. T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT. Blood. 2014;124:2735–43. https://doi.org/10.1182/blood-2014-04-571570.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malard F, Holler E, Sandmaier BM, Huang H, Mohty M. Acute graft-versus-host disease. Nat Rev Dis Prim. 2023;9:27. https://doi.org/10.1038/s41572-023-00438-1.

Article  PubMed  Google Scholar 

Lee SJ. Classification systems for chronic graft-versus-host disease. Blood. 2017;129:30–37. https://doi.org/10.1182/blood-2016-07-686642.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015;125:1333–8. https://doi.org/10.1182/blood-2014-10-609032.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transpl. 2016;51:610–1. https://doi.org/10.1038/bmt.2015.305.

Article  CAS  Google Scholar 

Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–28. https://doi.org/10.1182/blood.2022015850.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao Y, Chen W, Yu J, Pei S, Zhang Q, Shi J, et al. TP53 in MDS and AML: biological and clinical advances. Cancer Lett. 2024;588:216767 https://doi.org/10.1016/j.canlet.2024.216767.

Article  CAS  PubMed  Google Scholar 

Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110:4385–95. https://doi.org/10.1182/blood-2007-03-082404.

Article  CAS  PubMed  Google Scholar 

Hunter AM, Komrokji RS, Yun S, Al Ali N, Chan O, Song J, et al. Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes. Blood Adv. 2021;5:1017–28. https://doi.org/10.1182/bloodadvances.2020003508.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yoshizato T, Nannya Y, Atsuta Y, Shiozawa Y, Iijima-Yamashita Y, Yoshida K, et al. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood. 2017;129:2347–58. https://doi.org/10.1182/blood-2016-12-754796.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376:536–47. https://doi.org/10.1056/NEJMoa1611604.

Article  CAS  PubMed